Under the agreement, Clearside will receive an up front license fee of $5M & is eligible to receive up to an additional $30M as clinical & regulatory milestone payments
Moreover, Clearside is also eligible to receive up to $47.5M in three post-approval sales-based milestone payments if annual global sales of Avoralstat reach $2B, plus three tiers, mid-single digit royalties on annual global net sales incl. a top tier of >$1.5M
As a result of the partnership, BioCryst could assist patients with DME by using Clearside’s SCS Microinjector to administer Avoralstat directly to the back of the eye through the suprachoroidal region, which enables plasma kallikrein inhibition at the site of edema formation
Ref: Globenewswire | Image: BioCryst
Related News:- BioCryst Initiate the Patient Enrolment in Proof-of-Concept Trial of BCX10013 for the Treatment of Complement-Mediated Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
